XML 84 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 02, 2020
Feb. 28, 2017
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2018
Dec. 31, 2020
Jun. 07, 2018
May 31, 2018
Debt Instrument [Line Items]                
Amortization of deferred financing costs       $ 1,200,000        
Remaining unamortized deferred financing costs       9,900,000   $ 11,100,000    
Current portion of long-term debt       143,200,000   142,400,000    
Long-term debt, less current portion       2,388,800,000   2,419,600,000    
Portola Pharmaceuticals, Inc.                
Debt Instrument [Line Items]                
Deferred tax assets, royalty debt $ 42,400              
Repayments of debt 196,900,000              
Credit Agreement                
Debt Instrument [Line Items]                
Payments of financing costs         $ 53,100,000      
Credit Agreement | Revolving Credit Facility                
Debt Instrument [Line Items]                
Line of credit facility, maximum borrowing capacity             $ 1,000,000,000.0  
Letters of credit, amount outstanding       1,000,000.0        
Credit Agreement | Senior Secured Term Loan | Line of Credit                
Debt Instrument [Line Items]                
Debt instrument, principal amount             $ 2,612,500,000  
Debt Instrument, quarterly payment as a percent of total borrowings             5.00%  
Debt Instrument, Periodic Payment       (32,600,000)        
Outstanding debt       2,351,300,000        
Royalty-Based Financing Agreement | HealthCare Royalty Partners                
Debt Instrument [Line Items]                
Outstanding debt       $ 188,700,000   187,000,000.0    
Debt Instrument, Interest Rate, Effective Percentage       11.40%        
Interest Expense, Debt       $ 5,000,000.0        
Repayments of debt       3,300,000        
Current portion of long-term debt       16,300,000   15,500,000    
Long-term debt, less current portion       $ 172,400,000   171,500,000    
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc.                
Debt Instrument [Line Items]                
Outstanding debt 182,000,000.0              
Total repayment obligation as of December 31, 2020 276,900,000         $ 271,900,000    
Debt Instrument, Unamortized Discount 94,900,000              
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc.                
Debt Instrument [Line Items]                
Royalty Agreement, Closing Day Payment   $ 50,000,000.0            
Royalty Agreement, Milestone Payment Based On Regulatory Approval               $ 100,000,000.0
Royalty Agreement, Maximum Potential Royalty Payments As A Percentage Of Funding Received   195.00%            
Royalty Agreement, Maximum Potential Royalty Payments   $ 290,600,000            
Repayments of debt $ 13,700,000              
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc. | Minimum                
Debt Instrument [Line Items]                
Royalty Agreement, Tiered Royalty, Percent   4.20%            
Royalty-Based Financing Agreement | HealthCare Royalty Partners | Portola Pharmaceuticals, Inc. | Maximum                
Debt Instrument [Line Items]                
Royalty Agreement, Tiered Royalty, Percent   8.50%            
Royalty-Based Financing Agreement | Forecast [Member] | HealthCare Royalty Partners                
Debt Instrument [Line Items]                
Repayments of debt     $ 2,500,000